违反反垄断法，联环药业遭罚没6103.82万元

Core Viewpoint - The company, Lianhuan Pharmaceutical, has been penalized for engaging in anti-competitive practices related to the pricing of dexamethasone phosphate sodium raw materials, violating China's Anti-Monopoly Law [2][3]. Group 1: Regulatory Actions - The Tianjin Municipal Market Supervision Administration issued an administrative penalty decision against the company for forming a monopoly agreement to fix prices, which restricts competition in the sales of dexamethasone phosphate sodium [2]. - The company is required to cease illegal activities and has been fined a total of 61.0382 million yuan, which includes the confiscation of illegal gains amounting to 17.8992 million yuan and a fine based on 8% of the 2023 sales revenue [2]. Group 2: Financial Impact - The total penalty amount represents 2.83% of the company's audited revenue and 72.53% of its net profit attributable to shareholders for the most recent fiscal year [3]. - The penalty will reduce the company's net profit attributable to shareholders by 61.0382 million yuan for the fiscal year 2025 [3].